Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.36

-0.31 (-0.98%)

06:32
11/06/18
11/06
06:32
11/06/18
06:32

Mylan Q3 better than feared, recent selloff overdone, says JPMorgan

JPMorgan analyst Chris Schott views Mylan's Q3 results as "better than feared" and a "step in the right direction." While the company's North American business remains under pressure, year-over-year erosion for the business improved from Q2, overall gross margins showed solid year-over-year improvement and Mylan maintained its annual guidance, Schott tells investors in a post-earnings research note. The analyst views the recent weakness in the shares as overdone and keeps an Overweight rating on the name with a $45 price target. Looking beyond near-term challenges, Mylan is one of the better-positioned players in the space with a number of longer-term growth drivers in place, including biosimilars and the pending generic Advair approval, says Schott.

  • 13

    Nov

MYL Mylan
$31.36

-0.31 (-0.98%)

10/09/18
10/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Exelon (EXC) downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Citi. 2. CommScope (COMM) downgraded to Neutral from Buy at Goldman Sachs with analyst Mark Delaney saying he views the company's fundamental environment as "mixed" and views the stock's valuation as fair at current levels. 3. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger saying recent generics trends leave him seeing downside risk to consensus forecasts and Mylan's 2018 guidance. 4. Blackbaud (BLKB) downgraded to Market Perform from Outperform at Raymond James and JMP Securities as well as to Hold from Buy at Benchmark. 5. Kroger (KR) downgraded to Sell from Hold at Deutsche Bank while Smart & Final Stores (SFS) was downgraded to Hold from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/18
WELS
10/12/18
NO CHANGE
WELS
Market Perform
Merck returning Lantus biosimilar rights negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris sees a negative read-through for Mylan regarding yesterday's news of Merck Sharp & Dohme Research returning the rights to biosimilar Lantus to Samsung Bioepis. While some view this as a positive, as there will likely be one fewer competitor in the market if Mylan-Biocon make it to the U.S. market, that is a "simplistic and optimistic" take, Maris tells investors in a research note. The more important factor to consider is the "why" Merck dropped out, rather than the number of competitors, the analyst writes. He believes Merck returned the rights to Samsung Bioepis due to the deteriorating pricing environment and pricing outlook for insulin and Lantus biosimilars. Lilly's and Sanofi's manufacturing capacity, along with aggressive discounting, has created a "severe pricing environment," Maris contends. He believes that if Samsung Bioepis and Merck can't make the economics work, than one should be skeptical of Mylan and Biocon having substantial success. Maris has a Market Perform rating on Mylan shares.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

ISRG

Intuitive Surgical

$555.58

5.59 (1.02%)

09:53
02/22/19
02/22
09:53
02/22/19
09:53
Technical Analysis
Technical Take: Intuitive Surgical has a large active bullish pattern »

On a 5-year weekly chart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$24.76

2 (8.79%)

09:51
02/22/19
02/22
09:51
02/22/19
09:51
Upgrade
iQIYI rating change  »

iQIYI upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

MORN

Morningstar

$127.20

(0.00%)

09:50
02/22/19
02/22
09:50
02/22/19
09:50
Hot Stocks
Breaking Hot Stocks news story on Morningstar »

Morningstar trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$1.28

(0.00%)

09:50
02/22/19
02/22
09:50
02/22/19
09:50
Hot Stocks
Breaking Hot Stocks news story on Trillium Therapeutics »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

W

Wayfair

$143.50

26.36 (22.50%)

09:49
02/22/19
02/22
09:49
02/22/19
09:49
Recommendations
Wayfair analyst commentary  »

Wayfair's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

ASTE

Astec

$39.41

(0.00%)

, TEX

Terex

$35.65

0.06 (0.17%)

09:48
02/22/19
02/22
09:48
02/22/19
09:48
Recommendations
Astec ticks higher after Baird discusses possible takeover by Terex »

Terex (TEX) delaying its…

ASTE

Astec

$39.41

(0.00%)

TEX

Terex

$35.65

0.06 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$43.05

-4.22 (-8.93%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Nevro falls -9.2% »

Nevro is down -9.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPN

Aspen Aerogels

$3.60

(0.00%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Aspen Aerogels falls -12.8% »

Aspen Aerogels is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$8.86

-4.6 (-34.18%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Diplomat Pharmacy falls -34.1% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

PAGS

PagSeguro Digital

$25.10

2.24 (9.80%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
PagSeguro Digital rises 11.1% »

PagSeguro Digital is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$145.68

28.54 (24.36%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Wayfair rises 24.5% »

Wayfair is up 24.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

BYD

Boyd Gaming

$31.30

3.02 (10.68%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Boyd Gaming rises 11.4% »

Boyd Gaming is up 11.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MORN

Morningstar

$127.20

(0.00%)

09:45
02/22/19
02/22
09:45
02/22/19
09:45
Hot Stocks
Breaking Hot Stocks news story on Morningstar »

Morningstar trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

09:44
02/22/19
02/22
09:44
02/22/19
09:44
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

TSLA

Tesla

$291.18

(0.00%)

GS

Goldman Sachs

$196.40

(0.00%)

IDEX

Ideanomics

$1.76

(0.00%)

AMD

AMD

$23.92

(0.00%)

NVDA

Nvidia

$155.76

(0.00%)

OSTK

Overstock.com

$20.00

(0.00%)

DPW

DPW Holdings

$0.09

(0.00%)

KODK

Kodak

$2.98

(0.00%)

RIOT

Riot Blockchain

$3.53

(0.00%)

TEUM

Pareteum

$3.76

(0.00%)

SRAX

Social Reality

$3.73

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

  • 14

    Mar

  • 18

    Mar

  • 19

    Mar

LYB

LyondellBasell

$88.51

(0.00%)

09:41
02/22/19
02/22
09:41
02/22/19
09:41
Downgrade
LyondellBasell rating change  »

LyondellBasell downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$307,925.00

(0.00%)

, BRK.B

Berkshire Hathaway

$205.31

(0.00%)

09:40
02/22/19
02/22
09:40
02/22/19
09:40
Periodicals
Buffett's Berkshire set to lose about $3B from Kraft Heinz dive, CNBC says »

Warren Buffett's…

BRK.A

Berkshire Hathaway

$307,925.00

(0.00%)

BRK.B

Berkshire Hathaway

$205.31

(0.00%)

KHC

Kraft Heinz

$48.19

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$7.02

(0.00%)

, Z

Zillow

$35.03

(0.00%)

09:40
02/22/19
02/22
09:40
02/22/19
09:40
Options
Unusually active option classes on open February 22nd »

Unusual total active…

PBI

Pitney Bowes

$7.02

(0.00%)

Z

Zillow

$35.03

(0.00%)

DBX

Dropbox

$25.58

(0.00%)

W

Wayfair

$117.14

(0.00%)

ROKU

Roku

$51.47

(0.00%)

BIDU

Baidu

$171.72

(0.00%)

IQ

iQIYI

$22.76

(0.00%)

MDLZ

Mondelez

$48.39

(0.00%)

NEM

Newmont Mining

$35.39

(0.00%)

NIO

NIO Inc.

$7.62

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 20

    Mar

  • 25

    Mar

  • 28

    Mar

  • 28

    May

SID

CSN

09:38
02/22/19
02/22
09:38
02/22/19
09:38
Upgrade
CSN rating change  »

CSN upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

09:38
02/22/19
02/22
09:38
02/22/19
09:38
Downgrade
Kraft Heinz rating change  »

Kraft Heinz downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$16.56

-0.105 (-0.63%)

09:37
02/22/19
02/22
09:37
02/22/19
09:37
Conference/Events
House Committee on Homeland Security to hold a hearing »

The Cybersecurity,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

MGLN

Magellan Health

$70.81

-1.6 (-2.21%)

09:36
02/22/19
02/22
09:36
02/22/19
09:36
Hot Stocks
Magellan Health says will consider Starboard Value director nominees »

Magellan Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

EHTH

eHealth

$65.58

-0.28 (-0.43%)

09:36
02/22/19
02/22
09:36
02/22/19
09:36
Recommendations
eHealth analyst commentary  »

eHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

NXTM

NxStage Medical

$30.00

0.005 (0.02%)

, FMS

Fresenius Medical

$39.83

-0.06 (-0.15%)

09:33
02/22/19
02/22
09:33
02/22/19
09:33
Hot Stocks
NxStage Medical takeover by Fresenius Medical effective Feb. 21 »

NxStage Medical (NXTM)…

NXTM

NxStage Medical

$30.00

0.005 (0.02%)

FMS

Fresenius Medical

$39.83

-0.06 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

09:33
02/22/19
02/22
09:33
02/22/19
09:33
Downgrade
Kraft Heinz rating change  »

Kraft Heinz downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$17.76

0.12 (0.68%)

09:31
02/22/19
02/22
09:31
02/22/19
09:31
Recommendations
Wendy's analyst commentary  »

Wendy's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.